The Board of Directors at QAdvis is delighted to announce that Emma Axelsson has accepted the role of CEO, effective from February 1st 2022.
“It is truly a pleasure to hand over this executive role to Emma. She has over the years gained a huge competence in the Medical Device area and is truly a natural leader.
Emma has previously worked from a COO role and we are very confident that she will continue to spearhead our team efforts as a world class service provider of quality and regulatory services.”
–A Risk based roll-out plan for certain In Vitro Diagnostic medical devices and In-house devices
On 28 January 2022 the Regulation (EU) 2022/112 (CELEX number 32022R0112), amending new and updated transitional provisions to the IVD Regulation (EU) 2017/746, was published in the EU’s Official Journal after being signed on 25 January 2022 by the Presidents of the European Parliament and Council.
That means that this amending Regulation is now binding in its entirety and directly applicable in all Member States.
However, the amending Regulation does not change any requirements of the original IVD Regulation. It only changes requirement related dates of application identified in IVD Regulation (EU) 2017/746 articles 110, 112 and 113 for certain IVD medical devices including in-house devices.
The purpose of Regulation (EU) 2022/112 is to prevent disruption of supply of essential healthcare products in the context of the COVID-19 pandemic. All manufacturers need to control how the amending regulation affects transition times for each device.
QAdvis is a solution-oriented trusted service provider for the medical device and in vitro diagnostic device sector. To enable and maintain global market access, we can with high level of knowhow and expertise within quality management and regulatory affairs support your company to be in compliance with applicable regulations and requirements. QAdvis was founded in 2013 and is based in Sweden. We are certified according to ISO 13485:2016.